These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29503433)

  • 1. [Enzymological Studies on the Mechanisms of Pathogenesis of Diabetic Complications].
    Tanimoto T
    Yakugaku Zasshi; 2018; 138(3):405-415. PubMed ID: 29503433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
    Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications.
    Kovacikova L; Prnova MS; Majekova M; Bohac A; Karasu C; Stefek M
    Molecules; 2021 May; 26(10):. PubMed ID: 34066081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent studies of aldose reductase enzyme inhibition for diabetic complications.
    Suzen S; Buyukbingol E
    Curr Med Chem; 2003 Aug; 10(15):1329-52. PubMed ID: 12871133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical potential of aldose reductase inhibitors in diabetic neuropathy.
    Hamada Y; Nakamura J
    Treat Endocrinol; 2004; 3(4):245-55. PubMed ID: 16026107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CADD Studies in the Discovery of Potential ARI (Aldose Reductase Inhibitors) Agents for the Treatment of Diabetic Complications.
    Gupta SK; Tripathi PK
    Curr Diabetes Rev; 2023; 19(9):e180822207672. PubMed ID: 35993470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of diabetic autonomic neuropathy with red blood cell aldose reductase activity.
    Gupta P; Verma N; Bhattacharya S; Mahdi AA; Usman K; Tiwari S; Bhardwaj K
    Can J Diabetes; 2014 Feb; 38(1):22-5. PubMed ID: 24485209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.
    Bhadada SV; Vyas VK; Goyal RK
    Biomed Pharmacother; 2016 Oct; 83():221-228. PubMed ID: 27372406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic and molecular docking studies of loganin and 7-O-galloyl-D-sedoheptulose from Corni Fructus as therapeutic agents for diabetic complications through inhibition of aldose reductase.
    Lee CM; Jung HA; Oh SH; Park CH; Tanaka T; Yokozawa T; Choi JS
    Arch Pharm Res; 2015 Jun; 38(6):1090-8. PubMed ID: 25315636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased levels of aldose reductase in peripheral mononuclear cells from type 2 diabetic patients with microangiopathy.
    Hasegawa G; Obayashi H; Kitamura A; Hashimoto M; Shigeta H; Nakamura N; Kondo M; Nishimura CY
    Diabetes Res Clin Pract; 1999 Aug; 45(1):9-14. PubMed ID: 10499880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential use of aldose reductase inhibitors to prevent diabetic complications.
    Zenon GJ; Abobo CV; Carter BL; Ball DW
    Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics and molecular docking studies of an anti-diabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera.
    Jung HA; Islam MN; Lee CM; Oh SH; Lee S; Jung JH; Choi JS
    Chem Biol Interact; 2013 Oct; 206(1):55-62. PubMed ID: 23994501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analysis of aldose reductase in diabetic complications.
    Chung SS; Chung SK
    Curr Med Chem; 2003 Aug; 10(15):1375-87. PubMed ID: 12871135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications.
    Jannapureddy S; Sharma M; Yepuri G; Schmidt AM; Ramasamy R
    Front Endocrinol (Lausanne); 2021; 12():636267. PubMed ID: 33776930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural Compounds as Source of Aldose Reductase (AR) Inhibitors for the Treatment of Diabetic Complications: A Mini Review.
    Grewal AS; Thapa K; Kanojia N; Sharma N; Singh S
    Curr Drug Metab; 2020; 21(14):1091-1116. PubMed ID: 33069193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
    Kador PF; Wyman M; Oates PJ
    Prog Retin Eye Res; 2016 Sep; 54():1-29. PubMed ID: 27102270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldose reductase, still a compelling target for diabetic neuropathy.
    Oates PJ
    Curr Drug Targets; 2008 Jan; 9(1):14-36. PubMed ID: 18220710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythrocyte aldose reductase protein: a clue to elucidate risk factors for diabetic neuropathies independent of glycemic control.
    Takahashi Y; Tachikawa T; Ito T; Takayama S; Omori Y; Iwamoto Y
    Diabetes Res Clin Pract; 1998 Nov; 42(2):101-7. PubMed ID: 9886746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of ursolic acid derivatives on recombinant human aldose reductase.
    Lee EH; Popov SA; Lee JY; Shpatov AV; Kukina TP; Kang SW; Pan CH; Um BH; Jung SH
    Bioorg Khim; 2011; 37(5):637-44. PubMed ID: 22332359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aldose reductase in the polyol pathway: a potential target for the therapeutic intervention of diabetic complications].
    Nishimura-Yabe C
    Nihon Yakurigaku Zasshi; 1998 Mar; 111(3):137-45. PubMed ID: 9583077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.